Eryvac is registered for the control of Erysipelas polyarthritis in lambs and sheep.
Erysipelas infection may result in damage to the joints of sheep leading to arthritis.
For the control of erysipelas infection in lambs causing:
Scabigard Applicator
Hold the applicator at a 45deg angle to the skin and with both prongs touching the skin make a single 4 to 5cm long scratch on the bare skin surface. The scratch must be deep enough to cause skin damage but not draw blood.
Startect is the newest class of sheep drench and the only one to be released in combination for improved sustainability by managing resistance better.
Startect is a short-acting broad spectrum combination sheep drench that kills the most damaging worms, including those that are resistant to existing drenches.
It’s truly different
Two modes of action make it work differently to anything else to kill all the major production-limiting worms, including those that are resistant to other drenches.
Startect can be used every time an effective short-acting drench is required.
By installing it as the cornerstone drench in your program your operation will start gaining the significant benefits on offer.
Startect is the newest class of sheep drench and the only one to be released in combination for improved sustainability by managing resistance better.
Startect is a short-acting broad spectrum combination sheep drench that kills the most damaging worms, including those that are resistant to existing drenches.
It’s truly different
Two modes of action make it work differently to anything else to kill all the major production-limiting worms, including those that are resistant to other drenches.
Startect can be used every time an effective short-acting drench is required.
By installing it as the cornerstone drench in your program your operation will start gaining the significant benefits on offer.
Terramycin Pinkeye Aerosol contains oxytetracycline hydrochloride 2 mg/g in a non-CFC propellant.
A broad spectrum ANTIBIOTIC for treatment of eye infections of animals and in particular pinkeye conditions in cattle and sheep.
Terramycin is effective against Moraxella bovis and Rickettsia conjunctivae and has activity against a wide range of secondary invaders including Mycoplasma conjunctivae.
Approved Uses
Eye infections of all animals including infectious keratitis (pinkeye) of cattle and other infectious agents associated with these diseases. Bacterial wound contamination.
Features
1. How does the Dual Vaccinator work?
The Dual Vaccinator features two fixed 1mL barrels, one for Glanvac and one for Eryvac. When the plunger is depressed, Glanvac and Eryvac are combined at the rear of the vaccinator in a 2mL reservoir before travelling through a single barrel and needle. Delivering two vaccines at the same injection site saves time and maximises convenience. The Dual Vaccinator is only registered for use with Glanvac and Eryvac
2. What does co-administration of Glanvac and Eryvac using the Dual Vaccinator mean?
Co-administration of Glanvac and Eryvac means the two vaccines can now be delivered through the same needle at a single injection site. This means one less job at a busy time like lamb marking or pre-lambing. The Glanvac-Eryvac Dual Vaccinator is only registered for use with Glanvac and Eryvac. The APVMA has approved only Glanvac and Eryvac for use with the Dual Vaccinator based on Zoetis studies that demonstrated efficacy (measured using serological outcomes such as antibody titres) that was comparable to that of each vaccine administered separately, with an acceptable safety profile.
3. Can I use the Dual Vaccinator to administer other products?
No. Only Glanvac and Eryvac have been shown to be safe and effective when co-administered through the Dual Vaccinator. Therefore only Glanvac and Eryvac are registered by the APVMA for co-administration through the Dual Vaccinator. To achieve this registration, Zoetis conducted studies to prove that administration of Glanvac and Eryvac at the same injection site, through a single needle, resulted in efficacy comparable to that of each vaccine administered separately. In addition, these studies demonstrated that there were no impacts on safety. For example, there was no increase in injection site reactions when Glanvac and Eryvac were administered at the same site. Any other product has not been evaluated. There is a risk of injection site reactions and decreased vaccine efficacy where any other product is administered through the Dual Vaccinator